8-K: Phio Pharmaceuticals Corp. Receives Nasdaq Non-Compliance Notice Due to Low Share Price

Phio Pharmaceuticals Corp. has been notified by Nasdaq that it is not in compliance with the minimum bid price rule, as its stock price has remained below $1.00 for 30 consecutive business days.

Summary

• Phio Pharmaceuticals Corp. received a notification from Nasdaq on January 24, 2024, stating that the company is not in compliance with the Nasdaq Listing Rule 5550(a)(2).
• This rule requires the company's common stock to maintain a minimum closing bid price of $1.00.
• The company's stock price has been below $1.00 for 30 consecutive business days, triggering the non-compliance notice.
• Phio Pharmaceuticals has until July 22, 2024, to regain compliance by having its stock price close at or above $1.00 for at least 10 consecutive business days.
• The company intends to monitor its stock price and evaluate options to regain compliance.

Sentiment

Score: 3

Explanation: The document indicates a negative event (non-compliance notice) and potential delisting risk, which is unfavorable for investors. The company has a grace period to rectify the situation, but the overall sentiment is negative.

Positives

• The company has been given a grace period until July 22, 2024, to regain compliance.
• The notice does not immediately impact the trading of the company's stock.

Negatives

• The company's stock price has fallen below the required minimum of $1.00 for 30 consecutive business days.
• The company is now at risk of being delisted from the Nasdaq if it does not regain compliance.

Risks

• There is a risk that the company will not be able to increase its stock price to $1.00 or more for 10 consecutive business days by July 22, 2024.
• Failure to regain compliance could result in the company's stock being delisted from the Nasdaq Capital Market.
• The non-compliance notice could negatively impact investor confidence and further depress the stock price.

Future Outlook

The company intends to actively monitor its stock price and evaluate available options to regain compliance with the Minimum Bid Price Rule.

Management Comments

• The company intends to actively monitor the closing bid price of its common stock.
• The company will evaluate available options to regain compliance with the Minimum Bid Price Rule.

Industry Context

This type of non-compliance notice is not uncommon for companies with volatile stock prices, particularly in the biotechnology sector. It highlights the importance of maintaining a minimum share price to remain listed on major exchanges.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining their stock price above the minimum bid price required by exchanges like Nasdaq.
• Companies like Agenus Inc. and Cellectar Biosciences have also faced similar delisting risks due to low share prices.
• The 180-day grace period is a standard procedure for Nasdaq-listed companies to regain compliance.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment due to the non-compliance notice.
• The company's ability to raise capital may be negatively impacted.
• Employees may experience uncertainty about the company's future.

Next Steps

• The company will actively monitor the closing bid price of its common stock.
• The company will evaluate available options to regain compliance with the Minimum Bid Price Rule.

Key Dates

Keywords

Nasdaq, non-compliance, minimum bid price, delisting, stock price, compliance, PHIO